Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBIL1TY MELANOMA-07: Acasunlimab With or Without Pembrolizumab in Advanced Melanoma After Checkpoint Inhibitors
2025-520468-16-00Phase 2Completed
- Sponsor
- Genmab
- Start
- Oct 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2 trial of acasunlimab in cutaneous melanoma (CM) and melanoma (2 arms), sponsored by Genmab. Primary endpoint: Objective response rate (ORR). Started Oct 2025; status: completed.
02
Drugs
acasunlimab
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2025-520468-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520468-16-00.